Analysts Set Alder Biopharmaceuticals Inc (ALDR) PT at $20.75

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has been assigned a consensus recommendation of “Buy” from the twelve research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $20.75.

ALDR has been the subject of several recent research reports. BidaskClub raised shares of Alder Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 3rd. Goldman Sachs Group initiated coverage on shares of Alder Biopharmaceuticals in a research note on Tuesday, April 24th. They set a “neutral” rating and a $17.00 target price for the company. Zacks Investment Research lowered shares of Alder Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 1st. BMO Capital Markets set a $21.00 target price on shares of Alder Biopharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 9th. Finally, Canaccord Genuity restated a “buy” rating and set a $20.00 price target on shares of Alder Biopharmaceuticals in a report on Wednesday, May 9th.

ALDR stock opened at $18.50 on Tuesday. Alder Biopharmaceuticals has a 12 month low of $8.60 and a 12 month high of $19.60. The company has a market cap of $1.26 billion, a P/E ratio of -3.74 and a beta of 2.59. The company has a quick ratio of 13.30, a current ratio of 13.31 and a debt-to-equity ratio of 0.57.

Alder Biopharmaceuticals (NASDAQ:ALDR) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.50). equities analysts predict that Alder Biopharmaceuticals will post -4.97 earnings per share for the current fiscal year.

In other news, insider Mark James Litton sold 22,727 shares of the business’s stock in a transaction that occurred on Friday, June 1st. The shares were sold at an average price of $17.84, for a total transaction of $405,449.68. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider John A. Latham sold 24,999 shares of the business’s stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $15.48, for a total transaction of $386,984.52. Following the sale, the insider now owns 268,692 shares in the company, valued at approximately $4,159,352.16. The disclosure for this sale can be found here. Insiders have sold 84,209 shares of company stock worth $1,380,662 in the last 90 days. 17.40% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Teacher Retirement System of Texas bought a new stake in Alder Biopharmaceuticals in the fourth quarter worth $231,000. Bank of New York Mellon Corp lifted its holdings in shares of Alder Biopharmaceuticals by 1.5% during the fourth quarter. Bank of New York Mellon Corp now owns 320,029 shares of the biopharmaceutical company’s stock valued at $3,664,000 after purchasing an additional 4,873 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Alder Biopharmaceuticals by 8.5% during the fourth quarter. Geode Capital Management LLC now owns 559,850 shares of the biopharmaceutical company’s stock valued at $6,410,000 after purchasing an additional 43,864 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Alder Biopharmaceuticals by 176.3% during the fourth quarter. Alliancebernstein L.P. now owns 182,740 shares of the biopharmaceutical company’s stock valued at $2,092,000 after purchasing an additional 116,600 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of Alder Biopharmaceuticals by 25.3% during the fourth quarter. Deutsche Bank AG now owns 304,972 shares of the biopharmaceutical company’s stock valued at $3,491,000 after purchasing an additional 61,611 shares in the last quarter.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.

Further Reading: Trading Penny Stocks

Analyst Recommendations for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply